Therapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients

REFERENCES

• Montgomery RA, Hardy MA, Jordan SC, et al; Antibody Working Group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004;78:181–185.
   PubMed Web of Science ®Google Scholar
• Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009;9:1063–1071.
   PubMed Web of Science ®Google Scholar
• Ibernón M, Gil-Vernet S, Carrera M, et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant Proc. 2005;37:3743–3745.
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Cozzi E, West LJ, et al. Humoral immunity and antibody-mediated rejection in solid organ transplantation. Semin Immunol. 2011;23:224–234.
   PubMed Web of Science ®Google Scholar
• Péfaur J, Díaz P, Panace R, et al. Early and late humoral rejection: a clinicopathologic entity in two times. Transplant Proc. 2008;40:3229–3236.
   PubMed Web of Science ®Google Scholar
• Sun Q, Liu ZH, Ji S, et al. Late and early C4d-positive acute rejection: Different clinico-histopathological subentities in renal transplantation. Kidney Int. 2006;70:377– 383.
   PubMed Web of Science ®Google Scholar
• Gupta G, Abu Jawdeh BG, Racusen LC, et al. Late antibody-mediated rejection in renal allografts: Outcome after conventional and novel therapies. Transplantation 2014;97:1240–1246.
   PubMed Web of Science ®Google Scholar
• Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009;9:2520–2531.
   PubMed Web of Science ®Google Scholar
• Remport A, Ivanyi B, Mathe Z, et al. Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection. Nephrol Dial Transplant. 2014;0:1–9.
   Google Scholar
• Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol. 2001;12:574–582.
   PubMed Web of Science ®Google Scholar
• Regele H, Exner M, Watschinger B, et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant. 2001;16:2058–2066.
   PubMed Web of Science ®Google Scholar
• Böhmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol. 2002;13:1091–1099.
   PubMed Web of Science ®Google Scholar
• Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant. 2007;7:2124–2132.
   PubMed Web of Science ®Google Scholar
• Solez K, Colvin RB, Racusen LC, et al. Banff ‘05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN’). Am J Transplant. 2007;7:518–526.
   PubMed Web of Science ®Google Scholar
• Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: Current status and novel approaches. Am J Transplant. 2014;14:255–271.
   PubMed Web of Science ®Google Scholar
• Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753–760.
   PubMed Web of Science ®Google Scholar
• Ulger BV, Erbis H, Turkcu G, et al. Nebivolol ameliorates hepatic ischemia/reperfusion injury on liver but not on distant organs. J Invest Surg. 2015;28(5):245–252. doi:10.3109 /08941939.2015.1031923
   PubMed Web of Science ®Google Scholar
• Plenter RJ, Jain S, Nydam TL, et al. Revised arterial anastomosis for improving murine kidney transplant outcomes. J Invest Surg. 2015;28(4):208–214. doi:10.3109 /08941939.2014.1002641
   PubMed Web of Science ®Google Scholar
• Rodríguez Ferrero M, Rincón A, Bucalo L, et al. Treatment of acute antibody-mediated rejection: a single-center experience. Transplant Proc. 2010;42:2848–2850.
   PubMed Web of Science ®Google Scholar
• Burton SA, Amir N, Asbury A, et al. Treatment of antibody-mediated rejection in renal transplant patients: A clinical practice survey. Clin Transplant. 2015;29(2):118–123.
   PubMed Web of Science ®Google Scholar
• Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003;75:1490–1495.
   PubMed Web of Science ®Google Scholar
• Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242–251.
   PubMed Web of Science ®Google Scholar
• Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant. 2010;10:681–686.
   PubMed Web of Science ®Google Scholar
• Gubensek J, Buturovic-Ponikvar J, Kandus A, et al. Ponikvar. Plasma exchange and intravenous immunoglobulin in the treatment of antibody-mediated rejection after kidney transplantation: A single-center historic cohort study. Transplant Proc. 2013;45:1524–1527.
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000;70:887– 895.
   PubMed Web of Science ®Google Scholar
• Racusen LC, Colvin RB, Solez K, et al. Antibodymediated rejection criteria –an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708–714.
   PubMed Web of Science ®Google Scholar
• Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18:1046–1056.
   PubMed Web of Science ®Google Scholar
• Lederer SR, Kluth-Pepper B, Schneeberger H, et al. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int. 2001;59:334–341.
   PubMed Web of Science ®Google Scholar
• Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: New concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens. 2002;11:609–618.
   PubMed Web of Science ®Google Scholar
• Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: New diagnostic insights and standards. Am J Transplant. 2004;4:1562–1566.
   PubMedGoogle Scholar
• Tanriover B, Wright SE, Foster SV, et al. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transplant Proc. 2008;40:3393–3396.
   PubMed Web of Science ®Google Scholar
• Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibodymediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011;91:1218–1226.
   PubMed Web of Science ®Google Scholar